Based on this rationale, vorasidenib at a dose of 50 mg daily is being investigated in a phase 3 trial against placebo in patients with IDH-mutant grade 2 gliomas, who have received surgery since at least one year and not more than five years. The gene discussed is IDH1; the disease is central nervous system cancer.